(<i>R</i>)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors
Ha-Soon Choi(Genomics Institute of the Novartis Research Foundation), Valentina Molteni(Genomics Institute of the Novartis Research Foundation), Nanxin Li(Genomics Institute of the Novartis Research Foundation), Yi Fan(Huaqiao University), Tami Hood(Genomics Institute of the Novartis Research Foundation), Jon C. Loren(Genomics Institute of the Novartis Research Foundation), Celine Tompkins(Genomics Institute of the Novartis Research Foundation), Greg Chopiuk(Genomics Institute of the Novartis Research Foundation), AnneMarie Culazzo(Genomics Institute of the Novartis Research Foundation), Paul V. Rucker(Genomics Institute of the Novartis Research Foundation), Auzon Steffy(Genomics Institute of the Novartis Research Foundation), Tove Tuntland(Genomics Institute of the Novartis Research Foundation), Allen Li(Genomics Institute of the Novartis Research Foundation), Susan McCormack(Genomics Institute of the Novartis Research Foundation), Pamela Albaugh(Genomics Institute of the Novartis Research Foundation), Jennifer L. Harris(Genomics Institute of the Novartis Research Foundation), Bo Liu(Chengdu University of Traditional Chinese Medicine), F. Gessier(Genomics Institute of the Novartis Research Foundation), Jianwei Che(Genomics Institute of the Novartis Research Foundation), Mahavir Prashad(Genomics Institute of the Novartis Research Foundation), H. Martin Seidel(Genomics Institute of the Novartis Research Foundation), Van Phung(Genomics Institute of the Novartis Research Foundation), Andreas Kreusch(Genomics Institute of the Novartis Research Foundation), Jie Li(Qingdao University), Zhicheng Wang(Genomics Institute of the Novartis Research Foundation), Bin Hu(Ochsner Medical Center), Min Lu(South China Agricultural University), Fangxian Sun(Genomics Institute of the Novartis Research Foundation), Yong Jia(Harbin University of Science and Technology), Apurva Chaudhary(Genomics Institute of the Novartis Research Foundation), Francisco Adrián(HiFiBiO Therapeutics (United States)), Guoxun Liu(Genomics Institute of the Novartis Research Foundation)
Cited by 62
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
|Proceedings of the National Academy of Sciences|2013|833
Identification of Activating Transcription Factor 4 (ATF4) as an Nrf2-interacting Protein
|Journal of Biological Chemistry|2001|476
<i>In silico</i> activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen
|Proceedings of the National Academy of Sciences|2008|454